CHMP Positive Opinion for Sugemalimab in Stage III NSCLC
Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, remarked, “We are encouraged that the EMA review for our Stage III NSCLC indication has progressed so rapidly and positively. Coming just one year after sugemalimab’s first approval in Europe for first-line metastatic squamous and non-squamous NSCLC in 2024, this marks the second positive opinion and recommendation from CHMP. If approved, sugemalimab’s role as a core immunotherapy for lung cancer will be further solidified, significantly enhancing its market presence and commercial potential. We will work closely with our partners to expedite the full commercialization of sugemalimab across European markets, making this high-quality and accessible treatment option available to more patients.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo